Clinical Trials

Searchable database of currently enrolling clinical trials
From the Editor

From the Desk of Evan Yu: “Polycomb Complex Enhancer of Zeste 2 (EZH2), A Regulator of Lineage Reprogramming and A New Drug Target.”

Evan Y. Yu
August 09, 2019

Prostate cancer is a disease that universally responds to androgen deprivation therapy (ADT), as it is driven by androgens and their interaction with androgen receptors (AR). However, over time, prostate cancer will become resistant to ADT, delineating the castration-resistant disease state. The field has adapted to address this problem with even more potent hormonal therapies to cope with adrenal and intracrine androgen production. Hence, agents like abiraterone acetate, enzalutamide and apalutamide have regulatory approval in various prostate cancer disease states. However, when the disease eventually becomes resistant to these agents, multiple other mechanisms are at play that drives resistance.

READ MORE PREVIOUS ARTICLES

Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine
  • Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
  • Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance
  • Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe